Search Results - "Bossou, Ayoko R"

A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer by Bible, Keith C, Suman, Vera J, Menefee, Michael E, Smallridge, Robert C, Molina, Julian R, Maples, William J, Karlin, Nina J, Traynor, Anne M, Kumar, Priya, Goh, Boon Cher, Lim, Wan-Teck, Bossou, Ayoko R, Isham, Crescent R, Webster, Kevin P, Kukla, Andrea K, Bieber, Carolyn, Burton, Jill K, Harris, Pamela, Erlichman, Charles, the Mayo Phase 2 Consortium and Mayo Clinic Endocrine Malignances Disease Oriented Group

“…Context/Objectives: Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive…”
Get full text

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer by Isham, Crescent R, Bossou, Ayoko R, Negron, Vivian, Fisher, Kelly E, Kumar, Rakesh, Marlow, Laura, Lingle, Wilma L, Smallridge, Robert C, Sherman, Eric J, Suman, Vera J, Copland, John A, Bible, Keith C

“…Anaplastic thyroid cancer (ATC) has perhaps the worst prognosis of any cancer, with a median survival of only about 5 months regardless of stage. Pazopanib…”
Get more information

Development and Characterization of a Differentiated Thyroid Cancer Cell Line Resistant to VEGFR-Targeted Kinase Inhibitors by Isham, Crescent R, Netzel, Brian C, Bossou, Ayoko R, Milosevic, Dragana, Cradic, Kendall W, Grebe, Stefan K, Bible, Keith C

“…Background: Vascular endothelial growth factor-targeted kinase inhibitors have emerged as highly promising therapies for radioiodine-refractory metastatic…”
Get full text

A multi-institutional phase II trial of pazopanib monotherapy in advanced anaplastic thyroid cancer by Bible, Keith Christopher, Suman, VeraJean, Menefee, Michael E., Smallridge, Robert C., Molina, Julian R., Maples, William James, Karlin, Nina J., Traynor, Anne M., Kumar, Priya, Goh, Boon C., Lim, Wan-Teck, Bossou, Ayoko R, Isham, Crescent R, Webster, Kevin P., Kukla, Andrea K., Bieber, Carolyn, Burton, Jill K., Harris, Pamela Jo, Erlichman, Charles

“…Abstract only 5544 Background: Pazopanib, an orally bioavailable multitargeted inhibitor of kinases including VEGF-R, demonstrated impressive activity in…”
Get full text